Indivior provides FY2026 guidance: revenue $1.125B-$1.195B, Adj. EBITDA $535M-$575M

Indivior Pharmaceuticals, Inc.

Total net revenue expected $1,125M-$1,195M; SUBLOCADE net revenue $905M-$945M.
Non-GAAP operating expenses guided at $430M-$450M; adjusted EBITDA $535M-$575M.
Completed Phase I of Indivior Action Agenda with annual operating expense savings of at least $150M.
Shareholders approved U.K. to U.S. domicile change; expected effective Jan 26, 2026.
Concluded DOJ matter by paying $295M in full; entered Phase II focused on accelerating growth.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.